Exscientia · pitchdeck
Exscientia | Investor Presentation Deck | 69 slides
69 pages · 3 arc beats · 2 loops
Exscientia | Investor Presentation Deck | 69 slides
Exscientia · 2023-10 arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
1510152025303540455055606569
Deck intelligence map
3 coverage by narrative range · generated from this deck JSON
Narrative range 65 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem (Identify pain) 1 slides 100% 1/1 slides 100% 1/1 slides · 2 hits — 0/1 slides
100% 1/1 slides 100% 1/1 slides 100% 1/1 slides · 2 hits 100% 1/1 slides · 2 hits Agitate (Make it worse) 2 slides 100% 2/2 slides 100% 2/2 slides · 5 hits — 0/2 slides
50% 1/2 slides 100% 2/2 slides 100% 2/2 slides · 4 hits 100% 2/2 slides · 4 hits Solution (Provide relief) 62 slides 100% 62/62 slides 100% 62/62 slides · 320 hits — 0/62 slides
38.7% 24/62 slides · 28 hits 43.5% 27/62 slides · 29 hits 100% 62/62 slides · 63 hits 100% 62/62 slides · 63 hits Slide inventory
69 every slide · same image gating as the playbook
04
The slide uses a 3x2 grid layout to present quantitative achievements.show_traction
Open slide detailLoop · Golden Circle
05
The slide uses a dual-track timeline approach, separating pipeline progress from platform/corporate advancements.show_traction
Open slide detailLoop · Golden Circle
06
The slide uses a simple additive visual metaphor to represent the partnership.show_traction
Open slide detailLoop · Golden Circle
08
The slide uses a hub-and-spoke style diagram to show how different technical capabilities feed into and are informed by precision medicine.present_solution
09
The slide highlights the unique value proposition of each drug candidate in the pipeline.present_solution
10
The chart uses a horizontal bar format to indicate development stage (all currently in Phase 1/2).plan_implementation
11
The diagram is a concentric circle model representing value layers.present_solution
12
The slide uses a stepped arrow timeline to illustrate progression from simple small molecule design to complex biological automation.plan_implementation
13
Includes footnote regarding fixed term bank deposits and shares outstanding.analyze_data
15
The slide uses a complex flow diagram combining a linear process with two internal feedback loops (Active Learning).present_solution
16
The slide uses a circular process flow to represent a proprietary R&D pipeline.present_solution
17
The slide uses a process flow diagram to illustrate a specific patient success story.illustrate_case
18
The slide uses Kaplan-Meier curves to demonstrate clinical efficacy of the platform's drug prioritization.show_traction
19
The slide uses a horizontal process-like layout to showcase four distinct technical pillars.present_solution
20
The slide uses a circular flow diagram to represent the integration of AI and experimental biology.present_solution
21
The diagram illustrates a flywheel-like process of data integration leading to target identification.present_solution
22
The chart is a hierarchical clustering heatmap, commonly used in bioinformatics to show differential gene expression or patient response profiles.frame_problem
23
The slide illustrates a computational drug discovery workflow.present_solution
24
The diagram uses a hub-and-spoke model to show data integration, followed by a funnel for molecule generation and a circular feedback loop for active learning.present_solution
25
The slide features a 3D molecular visualization and a UI overlay representing various drug discovery parameters (Potency, Selectivity, etc.).present_solution
26
The scatter plot highlights a specific cluster of compounds selected by the AI that deviate from the standard Pareto front.present_solution
27
The slide uses a small multiples approach to show dose-response curves across multiple patient samples, followed by a summary plot comparing the two groups overanalyze_data
29
The title appears cut off at the bottom of the slide.present_solution
30
The slide features a 3D molecular visualization of the inhibitor.show_traction
31
The slide outlines a standard clinical trial progression from dose escalation to expansion, with a focus on establishing RP2D and evaluating ORR.plan_implementation
32
The slide uses a human anatomy diagram to map specific cancer types to their respective organ systems.size_opportunity
33
Includes a biological pathway diagram and a honeycomb-style indication map.size_opportunity
34
The slide uses a three-column layout to define the target product profile (TPP) criteria.present_solution
35
The table uses a color-coded heatmap (green/yellow/red) to indicate performance against criteria.compare_peers
36
The slide presents preclinical efficacy data for a CDK7 inhibitor ('617) in ovarian (OVCAR3) and triple-negative breast cancer (HCC70) models.show_traction
37
The main chart is a waterfall plot showing drug response scores across many samples. The right side details translational findings and a combination testing frashow_traction
38
The slide uses a heatmap to visualize synergy (green) vs no synergy (light green) across different drug combinations and patient samples.show_traction
39
Uses a Venn diagram to illustrate overlap between peripheral blood and tumour gene expression data.present_solution
40
The slide features a 3D molecular visualization.show_traction
41
The slide uses a bar chart to demonstrate efficacy at lower doses compared to a failed large pharma drug.show_traction
42
The slide uses a heatmap-style table to visualize performance metrics, highlighting the competitive advantage of the company's lead asset.compare_peers
43
The slide outlines a workflow from experimental data collection to AI-driven design and final compound nomination.present_solution
44
The background features a 3D molecular visualization, likely representing the LSD1 protein or the drug binding to it.plan_implementation
45
The slide uses a human anatomy diagram to map specific patient counts to disease locations.size_opportunity
47
Includes two scientific citations for the mechanism and brain penetration.present_solution
48
The slide uses a three-column layout to define the technical requirements for a drug candidate.present_solution
49
The slide uses a color-coded heatmap to visualize performance against a Target Product Profile (TPP).compare_peers
50
The slide uses a linear process flow to explain a complex computational chemistry workflow.present_solution
51
The chart uses a Pareto front to illustrate the trade-off between CNS score and Potency, highlighting that the 'best' molecules are not always the most informatpresent_solution
52
Includes statistical significance markers (*) on the tumour volume chart.show_traction
53
The slide uses two distinct chart types (dot plot and line chart) to demonstrate safety profiles.present_solution
54
The chart shows tumour volume over time for various dosing regimens compared to a vehicle control.present_solution
56
The slide uses a split-layout to contrast current operational status with overall program value proposition.summarize
57
The slide uses a stylized molecular visualization as a background element.plan_implementation
58
The slide uses a three-column layout to summarize the value proposition of the drug candidate.present_solution
62
The slide uses a heatmap-style table to compare performance against criteria. The UGT1A1 row is highlighted to emphasize the competitive advantage.compare_peers
63
The slide outlines a multi-stage pipeline: Initiate, Analyse, Evolve, 2D Models, 3D Models, and Active Learning.present_solution
64
The image shows a protein binding site with color-coded regions (Donor, Apolar, Acceptor) indicating chemical properties.present_solution
65
The chart shows dose-dependent tumour volume reduction over time compared to vehicle.show_traction
66
The chart shows tumour volume over time (D20-D30). The combination arm (teal) shows a flat line compared to the growth seen in monotherapy and vehicle arms.present_solution
69
This is a standard corporate contact/disclaimer slide.appendix